Brief: Bioversys Says Patent Claims For Its BV100 Drug Candidate Have Been Granted In China
31/03/2025 06:05
March 31 (Reuters) - BIOVERSYS AG BIOV.S: PATENT AROUND BIOVERSYS' BV100 DRUG CANDIDATE HAS BEEN GRANTED, PROTECTING PROPRIETARY RIFABUTIN IV FORMULATION TECHNOLOGY IN CHINA Source text: ID:nGNX5FjZnV Further company coverage: BIOV.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on BioVersys AG
See all newsBrief: Bioversys Expects Total Operating Loss Of CHF 40-45 Mln For FY2026
RCS - Bio Versys AG - BioVersys and partners’
Brief: BioVersys Announces BV100 Phase 3 Initiation And Provides Business Update
Brief: Bioversys Says Patent Claims For Its BV100 Drug Candidate Have Been Granted In China
UBS, Stifel start coverage of BioVersys with 'buy;' shares climb